New drug Y-3 tested in healthy people for first time in the U.S.
NCT ID NCT06770491
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of the experimental drug Y-3 in 20 healthy adults to see if it is safe and how the body processes it. Participants received either 40 mg, 60 mg, or a placebo. The study is complete and focused on gathering basic safety and drug-level information, not on treating any illness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Y-3
- What could go wrong
- This is a very early Phase 1 study with only 20 healthy people. It is designed to check safety and how the drug moves through the body, not to treat any disease. There is no guarantee Y-3 will ever be tested in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
20 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Medically documented as healthy at the time of screening as determined by their medical history, medical assessment, physical examination, 12-lead electrocardiogram (ECG), and clinical laboratory tests, etc. 2. Within 18-45 years at the time of informed consent, inclusive. 3. Body weight ≥ 50 kg for male and ≥ 45 kg for female, body mass index (BMI) within the range of 19 - 28 kg/m2, inclusive. 4. Fully understand and provide a signed informed consent before performing any study-related procedures. 5. Comply with the study and follow-up procedures. Exclusion Criteria: 1. Known allergy to Y-3 or any of its excipients. 2. Have disease history or current disease that may affect the safety evaluation of the subject or the internal process of the study drug, that the investigator judged to be of clinical significance, including the cardiovascular system, endocrine system, central nervous system, digestive system, respiratory system, hematological system, immunology, psychiatry, metabolic abnormalities, etc. 3. Clinically significant abnormal 12-lead electrocardiograms (ECG) and vital signs judged by the investigator. 4. Clinically significant abnormal laboratory tests (hematology, serum chemistry, coagulation, urinalysis, etc.) and other screening tests judged by the investigator. 5. Test positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, syphilis antibody or human immunodeficiency virus (HIV) antibody. 6. Alcoholics or regular drinkers within 6 months prior to screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol with 40% alcohol content or 150 mL of wine), or whose alcohol breath test results are greater than 0.0 mg/100 mL, or who cannot abstain from alcohol during the study. 7. Smokers, that is, those who smoke more than 3 cigarettes per day within 3 months prior to screening, or those who cannot comply with the prohibition of smoking during the study. 8. Current or former drug users, or positive urine screen for drugs of abuse at screening. 9. Have special requirements for diet and cannot follow the unified diet. 10. Drink too much tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months prior to screening, or who have consumed any diet (food or beverage) rich in grapefruit, pitaya and mango within 14 days prior to screening. 11. Have taken any prescription drug or over-the-counter drug, traditional Chinese medicine or herbal medicine, health products within 14 days prior to screening, or 5 half-lives, whichever is longer, before the first dose of study drug, or have received vaccine inoculation within 14 days prior to screening; or plan to inoculate vaccine during the study. 12. Participated in any other clinical trials within 3 months prior to screening. 13. Donation or loss of blood equal to or in excess of 200 mL within 3 months prior to screening. 14. Female subjects who have unprotected intercourse within 14 days prior to screening, or pregnant or lactating women. 15. Male subjects (or their partners) or female subjects have baby plans during the whole trial period and within 3 months after the end of the trial, or subjects are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, condoms, ligation, etc.) during the study. 16. Subjects voluntarily withdraw from the study due to personal reason, or subjects who the investigator believes are not suitable for enrollment for other reasons. 17. Suicidal ideation, history of suicidal behavior, or history of psychiatric comorbidities.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pharmacokinetic study in healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tranquil Clinical Research
Webster, Texas, 77598, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a potato reveal how your body handles medicines?
- Can a new cosmetic pass the skin allergy test?
- Can a new drug pair tame hodgkin lymphoma in older patients?
- Can a new injection shrink advanced solid tumors?
- Can a two-drug combo better tame prostate trouble?
- New vaginal capsule aims to tackle stubborn bacterial vaginosis